Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-β-hydroxycortisol:cortisol ratios

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1271-1276

  Burstein, Aaron H ^a   Reiss, William G ^a   Kantor, Eric ^b   Anderson, Gail D ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450; HYDROCORTISONE;

ADULT; AGING; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE BINDING; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; MENSTRUAL CYCLE; NORMAL HUMAN; POSTMENOPAUSE; PREMENOPAUSE; STATISTICAL ANALYSIS; URINALYSIS;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROCORTISONE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POSTMENOPAUSE; PREMENOPAUSE; TIME FACTORS;

EID: 0031782959     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-24.
2. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26(2):144-60.
3. Murray M. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23(2):132-46.
4. Gustavson LE, Benet LZ. Menopause: pharmacodynamics and pharmacokinetics. Exp Gerontol 1994;29(3/4):437-44.
5. Harris RZ, Tsunoda SM, Mroczkowski P, Wong H, Benet LZ. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996;59:429-35.
6. Oriba HA, Bucks DA, Maibach HI. Percutaneous absorption of hydrocortisone and testosterone on the vulva and forearm: effect of the menopause and site. Br J Dermatol 1996;134(2): 229-33.
7. Lien EA, Anker G, Ueland PM. Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. J Steroid Biochem Mol Biol 1995;51(3-4):175-81.
8. Tanaka Y, Sekiguchi M, Sawamoto T, et al. Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients. Eur J Drug Metab Pharmacokinet 1994;19(1):47-58.
9. Overgaard K, Agnudsei D, Hansen MA, Maiolie E, Christiansen C, Genvari C. Dose response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991;72(2): 344-9.
10. Anderson GD, Lin YX, Kantor E, Ojeman LM, Wilensky AJ. Menstrual cycle related changes in 6-β-OH-cortisol:cortisol [abstr]. Epilepsia 1995;36(suppl 4):56.
11. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986;39(5): 489-90.
12. Roots I, Holbe R, Hovermann W, et al. Quantitative determination by HPLC of urinary 6-β-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs. Eur J Clin Pharmacol 1979;16:63-7.
13. Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28(4):373-87.
14. Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 1989;36(1): 39-46.
15. Dolara P, Lodovici M, Salvadori M, Zaccara G, Muscas GC. Urinary 6-beta-OH-cortisol and paracetamol metabolites as a probe for assessing oxidation and conjugation of chemicals in humans. Pharmacol Res Communications 1987;19(4):261-73.
16. Saenger P. 6 beta-hydroxycortisol in random urine samples as an indicator of enzyme induction. Clin Pharmacol Ther 1983;34(6):818-21.
17. Nakamura J, Yakata M. Age- and sex-related differences in urinary excretion of 6 beta-hydroxycortisol in humans. Clin Chim Acta 1985;152(1-2):193-7.
18. Barton RN, Horan MA, Weijers JW, Sakkee AN, Roberts NA, van Bezooijen CF. Cortisol production rate and the urinary excretion of 17-hydroxycorticosteroids, free cortisol, and 6 beta-hydroxycortisol in healthy elderly men and women. J Gerontol 1993;38(5):M213-18.
19. Lee C. Urinary 6-β-hydroxycortisol in humans: analysis, biological variations, and reference ranges. Clin Biochem 1995;28(1):49-54.
20. Zhiri A, Wellman-Bednawska M, Siest G. ELISA of 6-beta-hydroxycortisol in human urine: diurnal variations and effects of antiepileptic therapy. Clin Chim Acta 1986;157:267-76.
21. Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992;52:265-73.
22. Schuetz EG, Schuetz JD, McLean W, et al. Expression of cytochrome P4503A4 in amphibian, rat, and human kidney. Arch Biochem Biophys 1992;294:206-14.
23. Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome p450IIIA5 (HLp3). Mol Pharmacol 1990;38: 207-13.
24. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.